全文获取类型
收费全文 | 42123篇 |
免费 | 2113篇 |
国内免费 | 300篇 |
专业分类
耳鼻咽喉 | 560篇 |
儿科学 | 767篇 |
妇产科学 | 696篇 |
基础医学 | 5417篇 |
口腔科学 | 880篇 |
临床医学 | 2811篇 |
内科学 | 11705篇 |
皮肤病学 | 632篇 |
神经病学 | 3143篇 |
特种医学 | 1501篇 |
外科学 | 7175篇 |
综合类 | 158篇 |
一般理论 | 1篇 |
预防医学 | 1083篇 |
眼科学 | 742篇 |
药学 | 2582篇 |
中国医学 | 76篇 |
肿瘤学 | 4607篇 |
出版年
2023年 | 219篇 |
2022年 | 165篇 |
2021年 | 905篇 |
2020年 | 499篇 |
2019年 | 608篇 |
2018年 | 891篇 |
2017年 | 691篇 |
2016年 | 815篇 |
2015年 | 856篇 |
2014年 | 1112篇 |
2013年 | 1416篇 |
2012年 | 2178篇 |
2011年 | 2458篇 |
2010年 | 1424篇 |
2009年 | 1261篇 |
2008年 | 2242篇 |
2007年 | 2369篇 |
2006年 | 2340篇 |
2005年 | 2276篇 |
2004年 | 2303篇 |
2003年 | 2147篇 |
2002年 | 2186篇 |
2001年 | 1069篇 |
2000年 | 1053篇 |
1999年 | 989篇 |
1998年 | 549篇 |
1997年 | 422篇 |
1996年 | 357篇 |
1995年 | 339篇 |
1994年 | 291篇 |
1993年 | 265篇 |
1992年 | 690篇 |
1991年 | 726篇 |
1990年 | 601篇 |
1989年 | 618篇 |
1988年 | 574篇 |
1987年 | 539篇 |
1986年 | 476篇 |
1985年 | 476篇 |
1984年 | 366篇 |
1983年 | 287篇 |
1982年 | 133篇 |
1980年 | 133篇 |
1979年 | 249篇 |
1978年 | 160篇 |
1977年 | 159篇 |
1974年 | 142篇 |
1972年 | 147篇 |
1971年 | 134篇 |
1969年 | 151篇 |
排序方式: 共有10000条查询结果,搜索用时 328 毫秒
1.
Hori Hiroki Ohta Asuka Matsui Honami Yano Kanako Morita-Tominaka Miyuki Linn Zayar Masumoto Daisuke Okumura Yosuke Okamura Satoshi Kurihara Kosuke Hayakawa Akira Rikiishi Takeshi Kobayashi Kyoko 《International journal of clinical oncology / Japan Society of Clinical Oncology》2022,27(1):245-252
International Journal of Clinical Oncology - The practice of cancer diagnosis disclosure to children has been changed with the times. The regulations of clinical trials in the 2000s might change... 相似文献
2.
Keiko Goto Yutaka Fujiwara Takeshi Isobe Naoko Chayahara Naomi Kiyota Toru Mukohara Yukari Tsubata Takamasa Hotta Kenji Tamura Noboru Yamamoto Hironobu Minami 《Cancer science》2019,110(6):1987-1994
Although dose reduction of S‐1 is recommended for patients with impaired renal function, dose modification for such patients has not been prospectively evaluated. The aim of the present study was to investigate the pharmacokinetic parameters of 5‐fluorouracil, 5‐chloro‐2,4 dihydroxypyridine and oteracil potassium, and to review the recommended dose modification of S‐1 in patients with renal impairment. We classified patients receiving S‐1 into 4 groups according to their renal function, as measured using the Japanese estimated glomerular filtration rate (eGFR) equation. The daily S‐1 dose was adjusted based on the patient's eGFR and body surface area. Blood samples were collected for pharmacokinetic analysis. A total of 33 patients were enrolled and classified into 4 groups as follows: 10 patients in cohort 1 (eGFR ≥ 80 mL/min/1.73 m2), 10 patients in cohort 2 (eGFR = 50‐79 mL/min/1.73 m2), 10 patients in cohort 3 (eGFR = 30‐49 mL/min/1.73 m2), and 3 patients in cohort 4 (eGFR < 30 mL/min/1.73 m2). Those in cohorts 3 and 4 treated with an adjusted dose of S‐1 showed a similar area under the curve for 5‐fluorouracil (941.9 ± 275.6 and 1043.5 ± 224.8 ng/mL, respectively) compared with cohort 2 (1034.9 ± 414.3 ng/mL). Notably, while there was a statistically significant difference between cohort 1 (689.6 ± 208.8 ng/mL) and 2 (P = 0.0474) treated with an equal dose of S‐1, there was no significant difference observed in the toxicity profiles of the cohorts. In conclusion, dose adjustment of S‐1 in patients with impaired renal function using eGFR is appropriate and safe. 相似文献
3.
4.
5.
Daisuke Ishibashi Takeshi Ishikawa Satoshi Mizuta Hiroya Tange Takehiro Nakagaki Tsuyoshi Hamada Noriyuki Nishida 《Neurotherapeutics》2020,17(4):1836
The accumulation of abnormal prion protein (PrPSc) produced by the structure conversion of PrP (PrPC) in the brain induces prion disease. Although the conversion process of the protein is still not fully elucidated, it has been known that the intramolecular chemical bridging in the most fragile pocket of PrP, known as the “hot spot,” stabilizes the structure of PrPC and inhibits the conversion process. Using our original structure-based drug discovery algorithm, we identified the low molecular weight compounds that predicted binding to the hot spot. NPR-130 and NPR-162 strongly bound to recombinant PrP in vitro, and fragment molecular orbital (FMO) analysis indicated that the high affinity of those candidates to the PrP is largely dependent on nonpolar interactions, such as van der Waals interactions. Those NPRs showed not only significant reduction of the PrPSc levels but also remarkable decrease of the number of aggresomes in persistently prion-infected cells. Intriguingly, treatment with those candidate compounds significantly prolonged the survival period of prion-infected mice and suppressed prion disease-specific pathological damage, such as vacuole degeneration, PrPSc accumulation, microgliosis, and astrogliosis in the brain, suggesting their possible clinical use. Our results indicate that in silico drug discovery using NUDE/DEGIMA may be widely useful to identify candidate compounds that effectively stabilize the protein.Electronic supplementary materialThe online version of this article (10.1007/s13311-020-00903-9) contains supplementary material, which is available to authorized users. 相似文献
6.
7.
8.
9.
10.
neurogenetics - Mediator (MED) is a key regulator of protein-coding gene expression, and mutations in MED subunits are associated with a broad spectrum of diseases. Because mutations in MED17... 相似文献